Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Joshua Knapp, Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza-Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Jorge Cortes, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 6398.

https://doi.org/10.1182/blood-2025-6398

Published: 2025

Journal Articles

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Ross Baker, Chih-Cheng Chen, Tsai-Yun Chen, Stanley Cheung, Hui-Hua Hsiao, Jae Hoon Lee, Ji Yun Lee, Sung-Eun Lee, Won Sik Lee, Lucia Masarova, Peter Tan, Shuhying Tan, Pankit Vachhani, Anne Marie Watson, Shang-Ju Wu, Jana Baskar, Joanna Leadbetter, Wolfgang Jarolimek

Blood (2025) 146 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2025-2027

Published: 2025

Journal Articles

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Blood (2025) 146 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2025-2024

Published: 2025

Journal Articles

Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-2021

Sachi Singhal, Rahul Mishra, Sankalp Arora, Noha Sharafeldin, Ruchi Desai, Tania Jain, Pankit Vachhani

Blood (2025) 146 (Supplement 1): 2048.

https://doi.org/10.1182/blood-2025-2048

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Jeanne Palmer, Jonathan How, Prithviraj Bose, Pankit Vachhani, Adam Mead, Jonathan Sillar, Aaron Gerds, Angela Fleischman, Caitlin O'Neill, Ross Baker, Ronald Hoffman, Shiangtung Jung, Jon Ruckle, Keyvan Yousefi, Sanjay Bhanot, Terry Barrett, Ruben Mesa

Blood (2025) 146 (Supplement 1): 82.

https://doi.org/10.1182/blood-2025-82

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Razan Mohty, Kendall Diebold, Todd Mudd, Maris Hardee, Jay Jarodiya, Katherine Parks, Kimo Bachiashvili, Manuel Espinoza-Gutarra, Sravanti Rangaraju, Pankit Vachhani, Omer Jamy

Blood (2025) 146 (Supplement 1): 5272.

https://doi.org/10.1182/blood-2025-5272

Published: 2025

Journal Articles

Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis

Anthony Selwyn Stein, Guru Subramanian Guru Murthy, Pankit Vachhani, Hannah Levavi, Sunil Iyer, Debbie Goldschmidt, Yipeng Gao, John Katsetos, Corey Pelletier, Tibor Kovacsovics

Blood (2025) 146 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2025-4612

Published: 2025

Journal Articles

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter, Pankit Vachhani, Alexander Coltoff, Anand Patel, Ashwin Kishtagari, Jeremy DiGennaro, Dahniel Sastow, Sandra Jones, Jay Jarodiya, Georgio Medawar, Shiv Shah, Naimisha Marneni, Megan Metzger, Ashley Yu, Rami Komrokji, John Mascarenhas

Blood (2025) 146 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2025-5600

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2025-5120

Published: 2025

Journal Articles

Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies

Pankit Vachhani, Nikolai Podoltsev, Ashwin Kishtagari, Purvi Suthar, Michael Vredenburg, Karisse Roman-Torres, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2025-2019

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Juan Carlos Hernandez Boluda, Catherine Ellis, Tom (sizhu) Liu, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5581.

https://doi.org/10.1182/blood-2025-5581

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

Trinayan Kashyap, Christopher Walker, Andrea Ellero, John Mascarenhas, Raajit Rampal, Pankit Vachhani, Yair Levy, Zhanet Grudeva-Popova, Pietro Taverna

Blood (2025) 146 (Supplement 1): 5537.

https://doi.org/10.1182/blood-2025-5537

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Journal Articles

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

Todd Mudd, Kendall Diebold, Sravanti Rangaraju, Kimo Bachiashvili, Pankit Vachhani, Manuel Espinoza-Gutarra, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2025-5220

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-2021

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only